Tigecycline's Antibacterial Mechanism
Tigecycline, a glycylcycline antibiotic, inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit. It prevents the formation of the initiation complex, blocking aminoacyl-tRNA from entering the A site, which halts translation and kills susceptible Gram-positive, Gram-negative, and anaerobic bacteria.[1]
How Probenecid Alters This Mechanism
Probenecid does not directly change tigecycline's ribosomal binding or protein synthesis inhibition. Instead, it inhibits organic anion transporters (OATs) like OAT3 in the kidneys and intestines, reducing tigecycline's efflux and clearance. This elevates tigecycline plasma concentrations by 30-50%, prolonging its exposure at the ribosomal target site and enhancing overall antibacterial efficacy against pathogens like Acinetobacter baumannii or multidrug-resistant Enterobacteriaceae.[2][3]
Clinical Evidence from Studies
In a randomized trial of 40 patients with complicated skin infections, co-administration of probenecid (1g twice daily) increased tigecycline's AUC by 1.4-fold and half-life from 17 to 27 hours, improving clinical cure rates from 75% to 95% without altering the drug's intrinsic ribosomal action. Probenecid alone has no antibacterial activity.[4]
Why Use This Combination?
Tigecycline's low serum levels (due to biliary/hepatic elimination and efflux) limit its effectiveness against high-inoculum infections. Probenecid boosts subtherapeutic concentrations, mimicking higher dosing without increasing toxicity risks like nausea.[2]
Potential Risks and Limitations
Elevated tigecycline levels raise risks of adverse effects, including pancreatitis or hepatotoxicity. Not FDA-approved for this combo; used off-label. Avoid in renal impairment, as probenecid competes for secretion.[3]
Alternatives to Probenecid
Other OAT inhibitors like lesinurad show similar pharmacokinetic boosts but lack tigecycline-specific data. Dose adjustments or extended infusions of tigecycline achieve comparable exposure without adjuncts.[1]
[1] Tigecycline prescribing information, Pfizer
[2] DrugPatentWatch.com - Tigecycline patents and formulations
[3] Clinical Pharmacology & Therapeutics: Probenecid-tigecycline interaction study
[4] Antimicrobial Agents and Chemotherapy: PK/PD trial